Cost-effectiveness analysis of the combination of low-dose nivolumab with triple metronomic chemotherapy for advanced head and neck squamous cell carcinoma in China.

ABSTRACT:

Background

The combination of low-dose nivolumab with triple metronomic chemotherapy (TMC-I) proposes a novel approach, potentially enhancing patient prognosis while mitigating financial barriers. The purpose of this study was to compare the cost-effectiveness of TMC-I compared to triple metronomic chemotherapy (TMC) in advanced head and neck squamous cell carcinoma (HNSCC) patients in China, the largest developing country.

Methods

A partitioned survival model (PSM) was developed based on a randomized clinical trial. Costs and utility were derived from open-access databases and literatures. The primary outcome was incremental cost-effectiveness ratio (ICER). A willingness-to-pay (WTP) threshold of ¥44,679/QALY based on supply-side and ¥134,037/QALY based on demand-side were

SUBMITTER: Cao Y 

PROVIDER: S-EPMC12433840 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature